The Effect of Fish Oil Oral Supplementation on Fat Metabolism in Obese Subjects on a Weight Loss Diet.
The Effect of Oral Supplementation with n-3 Fatty Acid Ethyl Esters on Lipoprotein Metabolism in Obese Subjects on a Weight Loss Diet.
Professor Gerald Watts
30 participants
Oct 4, 2010
Interventional
Conditions
Summary
The aim of this study is to examine the effect of weight loss plus oral supplementation of Omacor (Fish Oil) on postprandial lipid and lipoprotein transport in obese subjects. We hypothesis that in obese subjects, triglyceride production will be further reduced with Omacor oral supplementation in addition to weight loss in the postprandial state. All eligible participants will be on a weight loss period for 12 weeks followed by a weight maintanence period of 4 weeks. During these 16 weeks, each participant will be randomised into either weight loss alone (Group 1) or weight loss plus Omacor oral supplementation (Group 2).
Eligibility
Inclusion Criteria1
- Men and post-menopausal women aged 18-75 with Body Mass Index less than 45kg/m2 will be recruited. Post Menopausual will be defined by: no menstrual cycle for 1 year and Follicle Stimulating Hormone (FSH) greater than 30U/L, or if the subject has had a hysterectomy or surgical sterilisation. Central obesity will be defined as waist circumference greater than 88cm for women and greater than 102cm for men AND triglycerides greater than or equal to 1.5mmol/L and/or High-Density-Lipoprotein (HDL) cholesterol less than 1.0mmol/L for men and less than 1.3mmol/L for women.
Exclusion Criteria1
- Subjects with genetic hyperlipidemia, (eg Familial Hyperlipidemia, type III), Total cholesterol greater than 7mmol/L, proteinuria, hypothyroidism, alcoholism (greater than 30grams/day), creatinaemia (greater than 130micromol/L), hepatic dysfunction (Aspartate Transaminase (AST) or Alinine Transaminase (ALT) greater than 3 times the Upper Limit of Normal (ULN) and major systemic illness; pre-menopause women; use of steroids or other agents that may influence lipid metabolism, cardiovascular event within past 6 months, use of hypocaloric diets, anaemia; a history of intolerance to fish oil. Any gasto-intestinal surgery that would affect intestinal transit time and interpretation of postprandial lipaemia. Diabetics on medical management.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
2 parallel groups. Group 1 - Weight loss alone. Participants will undergo 12 weeks of weight loss followed by 4 weeks of weight maintenance. Over the 16 weeks, each participant will meet with a dietitian face-to-face every 2 weeks (each session approximately 30-60minutes) for professional dietary advice. Group 2 - Weight loss plus Fish Oil. Participants will undergo 12 weeks of weight loss followed by 4 weeks of weight maintenance. Over the 16 weeks, each participant will meet with a dietitian face-to-face every 2 weeks (each session approximately 30-60minutes) for professional dietary advice. Throughout this 16 weeks period, participants will also be provided with n-3 fatty acid ethyl esters (Fish Oil) oral supplementation (4g/day) to be consumed daily.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000750088